This recommendation is based on the largest randomized control trial in pediatric CKD patients studying BP targets: the Effect of Strict Blood Pressure Control and ACE Inhibition on the Progression of CKD in Pediatric Patients (ESCAPE) trial. This evidence concerns the gene ACE and chronic kidney disease.